Immunomic Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Immunomic Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH180942D
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immunomic Therapeutics Inc (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company's vaccines utilize the body's natural biochemistry to develop immune response including antibody production, cytokine release and critical immunological memory. It offers drugs for allergy vaccine therapy and oncology immunotherapy. ITI's product development pipeline also concentrates on the allergy product area for internal development including products for global cedar, juniper, cypress allergy, peanut allergy and flea allergy in dogs. The company also develops LAMP-vax technology vaccines that encode the expression of a fusion protein comprising the therapeutic antigen and the LAMP targeting protein. ITI is headquartered in Rockville, Maryland, the US.

Immunomic Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10

Immunomic Therapeutics Raises USD1 Million In Venture Financing 11

Immunomic Therapeutics Raises USD3 Million In Venture Financing 12

Immunomic Therapeutics Raises USD3 Million In Pre-Series B Financing Round 13

Immunomic Therapeutics Raises USD1.6 Million In Venture Financing 14

Immunomic Therapeutics Raises USD2.7 Million In Venture Financing 15

Immunomic Therapeutics Raises USD1.1 Million In Venture Financing 16

Immunomic Therapeutics Raises USD2 Million In Series A Financing 17

Partnerships 18

Immunomic Therapeutics Enters into Research Agreement with Duke University 18

Licensing Agreements 19

Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19

Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21

Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22

Equity Offering 23

Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23

Immunomic Therapeutics Inc-Key Competitors 24

Immunomic Therapeutics Inc-Key Employees 25

Immunomic Therapeutics Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Corporate Communications 27

Dec 13, 2017: Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board 27

Nov 29, 2017: Immunomic Therapeutics' Founder Appointed to Maryland Life Sciences Advisory Board 28

Jan 05, 2017: Immunomic Therapeutics' Scientific Advisory Board Expansion 29

Product News 30

07/31/2017: Immunomic Therapeutics Welcomes New Oncology Advisor 30

Clinical Trials 31

Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer 31

Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33

List of Figures

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immunomic Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10

Immunomic Therapeutics Raises USD1 Million In Venture Financing 11

Immunomic Therapeutics Raises USD3 Million In Venture Financing 12

Immunomic Therapeutics Raises USD3 Million In Pre-Series B Financing Round 13

Immunomic Therapeutics Raises USD1.6 Million In Venture Financing 14

Immunomic Therapeutics Raises USD2.7 Million In Venture Financing 15

Immunomic Therapeutics Raises USD1.1 Million In Venture Financing 16

Immunomic Therapeutics Raises USD2 Million In Series A Financing 17

Immunomic Therapeutics Enters into Research Agreement with Duke University 18

Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19

Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20

Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21

Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22

Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23

Immunomic Therapeutics Inc, Key Competitors 24

Immunomic Therapeutics Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Immunomic Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com